A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
ID Number 11-0784Principal Investigator(s)
Simon J. Hall
Department(s) or Division(s)
Individuals who are now receiving Sipuleucel-T (Provenge®) on a commercial basis will be asked to participate in a registry. This registry will collect demographic information disease status, medical history and prognostic factors. All side effects observed during or following first infusion through 30 days post final infusion, and any cerebrovascular events, will be reported. Individuals will continue to be followed every three months for safety, follow up cancer treatments and survival. They will be called on the telephone or questioned when they come in for a visit with their physician. Follow up will continue for a maximum of 3 years.
Cynthia Knauer RN, CRC
Recruiting Patients: Yes